This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

Well the bad news is that Blaven Technologies their Scottish subsidiary bases in Livingston has closed down as it failed to achieve revenue targets.Established 3 years ago it was MMI's nanotechnolgy arm with Billy Mitchell as chief executive but it failed to develop..it was supposed to be the next best idea according to DB at the time but hardly mentioned by him in the last couple of years.One thing is that now closed their costs next year will be reduced.
And the good news funny enough is also from Scotland in the shape of the collaboration with Edinburgh University to develop the ruthenium class of drugs which they reckon will be a blockbuster in the world of cancer drugs.
Over 15 compounds have been identified as showing high activity against difficult to treat cancer types as well as being useful against a wide range of tumours.
Also they have had success with Onco 0200 series of pineapple proteases with regard to ovarian cancer.
Genvax their new bio-baby dealing with Dna vaccines is already in clinical trials and Oncosense is due to commence this year and Viratis next year.

Still good potential and still risky then?
Are you still expecting up to 4 by end of 2005?

Its a high risk/high return Andy and could go to 400p next year or if it disappoints back to 40p...the next 15 months are critical.

Brokers note out this week ....

Any detail of whats in there Mitzy other than buy???????????.

cheers GF.

No idea at the mom GF.....

Anyway its moving up nicely Mitzy and Andy and shows our patience was well founded.

cheers GF.

Usually the days before the AGM and just after it puts on 10/20%...

When is it Mitzy its very soon isnt it?

cheers GF.

Cracking on this one today. Whatever that Brokers Buy note said it must have been good.

cheers GF.

Its the 27 th Oct in London GF....Cheapside...

Chears mate.

GF.

Im hoping that we have further news before the Agm which could push the price much higher..it could be the news were waiting for..

Looks like you know something Mitzy.

cheers GF.

It is just a hunch GF....

Ill bet.

cheers GF.

Probably one of the most risky shares I have held in 20 years of investing and trading, but I hope it comes good.

cheers GF.

morning folks

I am a long term holder of mmg since the 'bioscience innovation day's on ofex.

Your right goldfinger it is risky (although not compared to some of the dross i have held in the past)but it is constantly consolidating into a tidy little well run company.
My only regret with this one is that I did not top up at 2pence. It actually represents 50 p/c of my actively traded portfolio (8 stocks) which i know is to much but I do like the stock.

I think we could be in for a good day today but I am looking long term for the big institution interest which I am confident will come considering the gravity of the treatments undergoing research.

good luck.. rob

Nice to see you here rob, yes it could with a little push from the institutions.

It is up as I sapeak.

cheers GF.

Medical Marketing extends Edinburgh ruthenium cancer drug licensing deal
AFX


LONDON (AFX) - Medical Marketing International Group PLC said it has signed a deal with Edinburgh University, extending its licence to develop cancer drugs based on the precious metal Ruthenium.

MMI said it has exercised an option extending a 2002 agreement between its cancer subsidiary Oncosense and Edinburgh University.

It said the patent portfolio covers thousands of potential compounds. More than 140 compounds have already been tested against human cell lines, including those resistant to platinum-based drugs.

MMI said 12 lead compounds with significant activity have already been identified, and clinical trials candidate compounds will be chosen shortly.

email: newsdesk@afxnews.com

jm/


cheers GF.